Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
Active, not recruiting · NCT00336063 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm | Active, not recruiting | Phase 1 | 2026-08-19 | NCT00336063 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chinese University of Hong Kong-Prince of Wales Hospital | Shatin | Hong Kong | 3 |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | United States | 238 |
| National Cancer Center Hospital | Tokyo | Japan | 10 |
| National Cancer Centre Singapore | Singapore | Singapore | 61 |
| National University Hospital Singapore | Singapore | Singapore | 14 |